Skip to content

High blood pressure

Evaluation of the Efficacy of Sharbat-e-Unnab in Primary Hypertension.-An open labeled randomized standard controlled study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012871
Enrollment
40
Registered
2018-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Primary Hypertension

Interventions

Intervention1: Sharbat-e-Unnab: 25ml BD, oral Route, for the duration of 42 days Control Intervention1: Atenolol 25mg: Oral route, 1 OD, for the duration of 42 days.

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Known case of Primary hypertension with or without medication. Patients with H/O hypertension (stage-1 hypertension, ranging between systolic pressure 140 mm Hg to 159 mm Hg and/or diastolic pressure 90 mm Hg to 99 mmHg) as per reference card from (JNC-7). Age between 35 to 50 years. Both Gender.

Exclusion criteria

Exclusion criteria: Patients below 35 and above 50 years of age. Pregnancy and Lactation. Secondary Hypertension. Diabetes Mellitus. Other systemic and metabolic disorders. History of Myocardial Infarction and Ischemic Heart Disease. Bronchial Asthma and COPD.

Design outcomes

Primary

MeasureTime frame
reduction in systolic and diastolic blood prssureTimepoint: at every week for 6 weeks

Secondary

MeasureTime frame
Headache Dizziness Fatigue Palpitation Epistaxis Loss of libidoTimepoint: at every week for 6 weeks

Countries

India

Contacts

Public ContactDr Abdul Mobeen

National Institute of Unani Medicine

dr.mobeen@rediffmail.com8123143721

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026